Eaton Financial Holdings Company LLC Purchases New Holdings in United Therapeutics Corporation $UTHR

Key Points

• Eaton Financial Holdings has purchased a new position of 1,156 shares in United Therapeutics Corporation, valued at approximately $332,000, during the second quarter.
• Insider transactions reveal that executive vice president Paul A. Mahon and COO Michael Benkowitz sold 33,500 shares collectively, indicating a significant movement in company ownership.
• United Therapeutics' stock has recently experienced analyst target price adjustments, with Wells Fargo raising their target to $414.00 and HC Wainwright to $500.00, reflecting bullish sentiment.

Eaton Financial Holdings Company LLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,156 shares of the biotechnology company's stock, valued at approximately $332,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. SVB Wealth LLC acquired a new stake in United Therapeutics during the first quarter worth about $32,000. Geneos Wealth Management Inc. boosted its position in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 85 shares during the period. Sound Income Strategies LLC bought a new position in shares of United Therapeutics during the first quarter worth about $49,000. Brooklyn Investment Group increased its stake in shares of United Therapeutics by 103.2% in the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 98 shares during the period. Finally, WPG Advisers LLC acquired a new stake in United Therapeutics in the 1st quarter valued at approximately $60,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $308.75, for a total value of $3,396,250.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares in the company, valued at $11,356,133.75. This trade represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the business's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 176,435 shares of company stock valued at $65,503,807. Insiders own 10.30% of the company's stock.

United Therapeutics Stock Performance

UTHR opened at $414.73 on Tuesday. The firm has a market cap of $18.71 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 6.37 and a beta of 0.62. The firm's 50-day simple moving average is $331.90 and its 200-day simple moving average is $311.38. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $436.95.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. During the same quarter last year, the firm posted $5.85 EPS. The business's revenue was up 11.7% on a year-over-year basis. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on UTHR. Wells Fargo & Company upped their target price on United Therapeutics from $295.00 to $414.00 and gave the stock an "equal weight" rating in a research report on Wednesday, September 3rd. HC Wainwright lifted their target price on United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a report on Friday, September 5th. Morgan Stanley reduced their target price on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a report on Thursday, July 10th. Bank of America raised their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 2nd. Finally, Cantor Fitzgerald lifted their target price on United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a research note on Wednesday, September 10th. Nine equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $438.85.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.